Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF Receivables

The latest receivables for GERM is $1.5B as of June 2026. That compares with $120M in the prior-year period — up 1151.1% year over year. Investors often review this figure alongside Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's historical trend and sector peers before judging valuation or financial health.

Over the past year, GERM's receivables moved from $120M to $1.5B — a 1151.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's operating scale or balance-sheet position.

A receivables figure of $1.5B for GERM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GERM's receivables ($1.5B), review year-over-year change from $120M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.